Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study
äºBeneficial MicrobesSearch for other papers by M. Ratna Sudha in
Current site
Google Scholar
Search for other papers by N. Jayanthi in
Current site
Google Scholar
Search for other papers by M. Aasin in
Current site
Google Scholar
Search for other papers by R.D. Dhanashri in
Current site
Google Scholar
Search for other papers by T. Anirudh in
Current site
Google Scholar
The efficacy of the probiotic strain, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) was evaluated in children. A total of 141 children of either sex in the age group 4-12 years, diagnosed with IBS according to the Rome III criteria, participated in the double-blind randomised controlled trial. Children received either B. coagulans Unique IS2 chewable tablets or placebo once daily for eight weeks followed by a two week follow-up period. Reduction in pain intensity as well as other symptoms associated with Irritable Bowel Syndrome like abdominal discomfort, bloating, distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, and bowel habit satisfaction were assessed. B. coagulans Unique IS2 treated group showed a greater reduction in pain scores as evaluated by a weekly pain intensity scale. There was a significant reduction (P<0.0001) in pain intensity in the probiotic treated group (7.6±0.98) as compared to the placebo group (4.2±1.41) by the end of the treatment period (8 weeks). There was also a significant improvement in stool consistency as well as reduction in abdominal discomfort, bloating, staining, urgency, incomplete evacuation and passage of gas. Bowel habit satisfaction and global assessment of relief was also observed in the B. coagulans Unique IS2 treated group as compared to the placebo group. This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Ara, K., Meguro, S., Hase, T., Tokimitsu, I., Otsuji, K., Kawai, S., Ito, S. and Iino, H., 2002. Effect of spore-bearing lactic acid-forming bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats. Microbial Ecology in Health and Disease 14: 4-13.
'Effect of spore-bearing lactic acid-forming bacteria (Bacillus coagulans SANK 70258) administration on the intestinal environment, defecation frequency, fecal characteristics and dermal characteristics in humans and rats ' () 14 Microbial Ecology in Health and Disease : 4 -13.
-
Balamtekın, N., Baysoy, G., Uslu, N., Orhan, D., Akçören, Z., Ãzen, H., Gürakan, F., Saltik-Temızel, Ä°.N. and Yüce, A., 2012. Fecal calprotectin concentration is increased in children with celiac disease: relation with histopathological findings. Turkish Journal of Gastroenterology 23: 503-508.
'Fecal calprotectin concentration is increased in children with celiac disease: relation with histopathological findings ' () 23 Turkish Journal of Gastroenterology : 503 -508.
-
Canavan, C., West, J. and Card, T.R., 2014. The epidemiology of Irritable bowel syndrome. Clinical Epidemiology 6: 71-80.
'The epidemiology of Irritable bowel syndrome ' () 6 Clinical Epidemiology : 71 -80.
-
Caplan, A., Walker, L. and Rasquin, A., 2005. Validation of the pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms. Journal of Pediatric Gastroenterology and Nutrition 41: 305-316.
'Validation of the pediatric Rome II criteria for functional gastrointestinal disorders using the questionnaire on pediatric gastrointestinal symptoms ' () 41 Journal of Pediatric Gastroenterology and Nutrition : 305 -316.
-
Collins, S.M., 2014. A role for the gut microbiota in IBS. Nature Reviews Gastroenterology and Hepatology 11: 497-505.
'A role for the gut microbiota in IBS ' () 11 Nature Reviews Gastroenterology and Hepatology : 497 -505.
-
Didari, T., Mozaffari, S., Nikfar, S. and Abdollahi, M., 2015. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World Journal of Gastroenterology 21: 3072-3084.
'Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis ' () 21 World Journal of Gastroenterology : 3072 -3084.
-
Dolin, B.J., 2009. Effects of a proprietary B. coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods and Findings in Experimental and Clinical Pharmacology 31: 655-659.
'Effects of a proprietary B. coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome ' () 31 Methods and Findings in Experimental and Clinical Pharmacology : 655 -659.
-
El-Matary, W., Spray, C. and Sandhu, B., 2004. Irritable bowel syndrome: the commonest cause of recurrent abdominal pain in children. European Journal of Pediatrics 163: 584-588.
'Irritable bowel syndrome: the commonest cause of recurrent abdominal pain in children ' () 163 European Journal of Pediatrics : 584 -588.
-
Enck, P., Klosterhalfen, S. and Martens, U., 2011. Probiotic therapy of the irritable bowel syndrome. Deutsche Medizinische Wochenschrift 136: 371-375.
'Probiotic therapy of the irritable bowel syndrome ' () 136 Deutsche Medizinische Wochenschrift : 371 -375.
-
Francavilla, R., Miniello, V., Magistà , A.M., De Canio, A., Bucci, N., Gagliardi, F., Lionetti, E., Castellaneta, S., Polimeno, L., Peccarisi, L. and Indrio, F., 2010. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 126: e1445-e1452.
'A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain ' () 126 Pediatrics : e1445 -e1452.
-
Gareau, M.G., Sherman, P.M. and Walker, W.A., 2010. Probiotics and the gut microbiota in intestinal health and disease. Nature Reviews Gastroenterology and Hepatology 7: 503-514.
'Probiotics and the gut microbiota in intestinal health and disease ' () 7 Nature Reviews Gastroenterology and Hepatology : 503 -514.
-
Guandalini, S., Magazzu, G., Chiaro, A., La Balestra, V., Di Nardo, G., Gopalan, S., Sibal, A., Romano, C., Canani, R.B., Lionetti, P. and Setty, M., 2010. VSL# 3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. Journal of Pediatric Gastroenterology and Nutrition 51: 24-30.
'VSL# 3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study ' () 51 Journal of Pediatric Gastroenterology and Nutrition : 24 -30.
-
Hun, L., 2009. B. coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgraduate Medicine 121: 119-124.
'B. coagulans significantly improved abdominal pain and bloating in patients with IBS ' () 121 Postgraduate Medicine : 119 -124.
-
Hyams, J.S., Burke, G., Davis, P.M., Rzepski, B. and Andrulonis, P.A., 1996. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. Journal of Pediatrics 129: 220-226.
'Abdominal pain and irritable bowel syndrome in adolescents: a community-based study ' () 129 Journal of Pediatrics : 220 -226.
-
Jurenka, J.S., 2012. B. coagulans. Alternative Medicine Review 17: 76-81.
'B. coagulans ' () 17 Alternative Medicine Review : 76 -81.
-
Karabulut, G.S., BeÅer, Ã.F., Erginöz, E., Kutlu, T., ÃokuÄraÅ, F.Ã. and Erkan, T., 2013. The incidence of irritable bowel syndrome in children using the Rome III criteria and the effect of trimebutine treatment. Journal of Neurogastroenterology and Motility 19: 90-93.
'The incidence of irritable bowel syndrome in children using the Rome III criteria and the effect of trimebutine treatment ' () 19 Journal of Neurogastroenterology and Motility : 90 -93.
-
Korterink, J.J., Ockeloen, L., Benninga, M.A., Tabbers, M.M., Hilbink, M. and Deckers-Kocken, J.M., 2014. Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis. Acta Paediatrica 103: 365-372.
'Probiotics for childhood functional gastrointestinal disorders: a systematic review and meta-analysis ' () 103 Acta Paediatrica : 365 -372.
-
Lutgendorff, F., Akkermans, L. and Soderholm, J.D., 2008. The role of microbiota and probiotics in stress-induced gastrointestinal damage. Current Molecular Medicine 8: 282-298.
'The role of microbiota and probiotics in stress-induced gastrointestinal damage ' () 8 Current Molecular Medicine : 282 -298.
-
Miele, E., Simeone, D., Marino, A., Greco, L., Auricchio, R., Novek, S.J. and Staiano, A., 2004. Functional gastrointestinal disorders in children: an Italian prospective survey. Pediatrics 114: 73-78.
'Functional gastrointestinal disorders in children: an Italian prospective survey ' () 114 Pediatrics : 73 -78.
-
Moayyedi, P., Ford, A.C., Talley, N.J., Cremonini, F., Foxx-Orenstein, A.E., Brandt, L.J. and Quigley, E.M., 2010. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325-332.
'The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review ' () 59 Gut : 325 -332.
-
Müller-Lissner, S., Koch, G., Talley, N.J., Drossman, D., Rueegg, P., Dunger-Baldauf, C. and Lefkowitz, M., 2003. Subjectâs global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. Journal of Clinical Epidemiology 56: 310-316.
'Subjectâs global assessment of relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials ' () 56 Journal of Clinical Epidemiology : 310 -316.
-
Ortiz-Lucas, M., TobÃas, A., Saz, P. and Sebastián, J.J., 2013. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Revista Espanola de Enfermedades Digestivas 105: 19-36.
'Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis ' () 105 Revista Espanola de Enfermedades Digestivas : 19 -36.
-
Rasquin, A., Di Lorenzo, C., Forbes, D., Guiraldes, E., Hyams, J.S., Staiano, A. and Walker, L.S., 2006. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 130: 1527-1537.
'Childhood functional gastrointestinal disorders: child/adolescent ' () 130 Gastroenterology : 1527 -1537.
-
Sandhu, B.K. and Paul, S.P., 2014. Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment. World Journal of Gastroenterology 20: 6013.
'Irritable bowel syndrome in children: pathogenesis, diagnosis and evidence-based treatment ' () 20 World Journal of Gastroenterology : 6013.
-
Saneian, H., Pourmoghaddas, Z., Roohafza, H. and Gholamrezaei, A., 2015. Synbiotic containing B. coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterology and Hepatology from Bed to Bench 8: 56-65.
'Synbiotic containing B coagulans and fructo-oligosaccharides for functional abdominal pain in children ' () 8 Gastroenterology and Hepatology from Bed to Bench : 56 -65.
-
Sekirov, I., Russell, S.L., Antunes, L.C.M. and Finlay, B.B., 2010. Gut microbiota in health and disease. Physiological Reviews 90: 859-904.
'Gut microbiota in health and disease ' () 90 Physiological Reviews : 859 -904.
-
Spiller, R. and Garsed, K., 2009. Post-infectious irritable bowel syndrome. Gastroenterology 136: 1979-1988.
'Post-infectious irritable bowel syndrome ' () 136 Gastroenterology : 1979 -1988.
-
Tang, Y.R., Yang, W.W., Liang, M.L., Xu, X.Y., Wang, M.F. and Lin, L., 2012. Age-related symptom and life quality changes in women with irritable bowel syndrome. World Journal of Gastroenterology 18: 7175-7183.
'Age-related symptom and life quality changes in women with irritable bowel syndrome ' () 18 World Journal of Gastroenterology : 7175 -7183.
-
Whelan, K., 2011. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Current Opinion in Clinical Nutrition and Metabolic Care 14: 581-587.
'Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews ' () 14 Current Opinion in Clinical Nutrition and Metabolic Care : 581 -587.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 2781 | 622 | 41 |
| å ¨ææµè§æ¬¡æ° | 70 | 13 | 0 |
| PDFä¸è½½æ¬¡æ° | 118 | 31 | 0 |
Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled study
äºBeneficial MicrobesSearch for other papers by M. Ratna Sudha in
Current site
Google Scholar
PubMed
Search for other papers by N. Jayanthi in
Current site
Google Scholar
PubMed
Search for other papers by M. Aasin in
Current site
Google Scholar
PubMed
Search for other papers by R.D. Dhanashri in
Current site
Google Scholar
PubMed
Search for other papers by T. Anirudh in
Current site
Google Scholar
PubMed
The efficacy of the probiotic strain, Bacillus coagulans Unique IS2 in the treatment of Irritable Bowel Syndrome (IBS) was evaluated in children. A total of 141 children of either sex in the age group 4-12 years, diagnosed with IBS according to the Rome III criteria, participated in the double-blind randomised controlled trial. Children received either B. coagulans Unique IS2 chewable tablets or placebo once daily for eight weeks followed by a two week follow-up period. Reduction in pain intensity as well as other symptoms associated with Irritable Bowel Syndrome like abdominal discomfort, bloating, distension, sense of incomplete evacuation, straining at stool, urgency of bowel movement, passage of gas and mucus, and bowel habit satisfaction were assessed. B. coagulans Unique IS2 treated group showed a greater reduction in pain scores as evaluated by a weekly pain intensity scale. There was a significant reduction (P<0.0001) in pain intensity in the probiotic treated group (7.6±0.98) as compared to the placebo group (4.2±1.41) by the end of the treatment period (8 weeks). There was also a significant improvement in stool consistency as well as reduction in abdominal discomfort, bloating, staining, urgency, incomplete evacuation and passage of gas. Bowel habit satisfaction and global assessment of relief was also observed in the B. coagulans Unique IS2 treated group as compared to the placebo group. This study demonstrates the efficacy of B. coagulans Unique IS2 in reducing the symptoms of Irritable Bowel Syndrome in children in the age group of 4-12 years.
| å ¨é¨æé´ | è¿å»ä¸å¹´ | è¿å»30天 | |
|---|---|---|---|
| æè¦æµè§æ¬¡æ° | 2781 | 622 | 41 |
| å ¨ææµè§æ¬¡æ° | 70 | 13 | 0 |
| PDFä¸è½½æ¬¡æ° | 118 | 31 | 0 |
